| Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation DJ Graham, ME Reichman, M Wernecke, R Zhang, MR Southworth, ... Circulation 131 (2), 157-164, 2015 | 879 | 2015 |
| Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation DJ Graham, ME Reichman, M Wernecke, YH Hsueh, R Izem, ... JAMA internal medicine 176 (11), 1662-1671, 2016 | 395 | 2016 |
| Comparative risk of anaphylactic reactions associated with intravenous iron products C Wang, DJ Graham, RC Kane, D Xie, M Wernecke, M Levenson, ... Jama 314 (19), 2062-2068, 2015 | 249 | 2015 |
| Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation DJ Graham, E Baro, R Zhang, J Liao, M Wernecke, ME Reichman, M Hu, ... The American journal of medicine 132 (5), 596-604. e11, 2019 | 187 | 2019 |
| Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017–2018 HS Izurieta, Y Chillarige, J Kelman, Y Wei, Y Lu, W Xu, M Lu, D Pratt, ... The Journal of infectious diseases 220 (8), 1255-1264, 2019 | 172 | 2019 |
| Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing postinfluenza deaths during 2012–2013 and 2013–2014 DK Shay, Y Chillarige, J Kelman, RA Forshee, IM Foppa, M Wernecke, ... The Journal of infectious diseases 215 (4), 510-517, 2017 | 133 | 2017 |
| Relative effectiveness of influenza vaccines among the United States elderly, 2018–2019 HS Izurieta, Y Chillarige, J Kelman, Y Wei, Y Lu, W Xu, M Lu, D Pratt, ... The Journal of infectious diseases 222 (2), 278-287, 2020 | 86 | 2020 |
| Natural history of coronavirus disease 2019: risk factors for hospitalizations and deaths among> 26 million US Medicare beneficiaries HS Izurieta, DJ Graham, Y Jiao, M Hu, Y Lu, Y Wu, Y Chillarige, ... The Journal of infectious diseases 223 (6), 945-956, 2021 | 85 | 2021 |
| Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the Medicare population ages 65 years and older HS Izurieta, M Wernecke, J Kelman, S Wong, R Forshee, D Pratt, Y Lu, ... Clinical Infectious Diseases 64 (6), 785-793, 2017 | 84 | 2017 |
| Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure HS Izurieta, X Wu, R Forshee, Y Lu, HM Sung, PE Agger, Y Chillarige, ... Clinical Infectious Diseases 73 (6), 941-948, 2021 | 72 | 2021 |
| Comparative effectiveness of influenza vaccines among US Medicare beneficiaries ages 65 years and older during the 2019–2020 season HS Izurieta, M Lu, J Kelman, Y Lu, A Lindaas, J Loc, D Pratt, Y Wei, ... Clinical Infectious Diseases 73 (11), e4251-e4259, 2021 | 69 | 2021 |
| Idelalisib for treatment of relapsed follicular lymphoma and chronic lymphocytic leukemia: a comparison of treatment outcomes in clinical trial participants vs medicare … ST Bird, F Tian, N Flowers, D Przepiorka, R Wang, TH Jung, Z Kessler, ... JAMA oncology 6 (2), 248-254, 2020 | 52 | 2020 |
| Association between changes in CMS reimbursement policy and drug labels for erythrocyte-stimulating agents with outcomes for older patients undergoing hemodialysis covered by … C Wang, R Kane, M Levenson, J Kelman, M Wernecke, JY Lee, ... JAMA internal medicine 176 (12), 1818-1825, 2016 | 39 | 2016 |
| Risk of Guillain-Barré syndrome following recombinant zoster vaccine in Medicare beneficiaries R Goud, B Lufkin, J Duffy, B Whitaker, HL Wong, J Liao, AC Lo, ... JAMA internal medicine 181 (12), 1623-1630, 2021 | 36 | 2021 |
| Severe hypoglycemia risk with long-acting insulin analogs vs neutral protamine Hagedorn insulin MC Bradley, Y Chillarige, H Lee, X Wu, S Parulekar, S Muthuri, ... JAMA Internal Medicine 181 (5), 598-607, 2021 | 36 | 2021 |
| Effect of age on relative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries aged≥ 65 years Y Lu, Y Chillarige, HS Izurieta, Y Wei, W Xu, M Lu, HM Sung, A Lindaas, ... The Journal of infectious diseases 220 (9), 1511-1520, 2019 | 30 | 2019 |
| Uptake of the biologic filgrastim and its biosimilar product among the Medicare population S Kozlowski, N Birger, S Brereton, SJ McKean, M Wernecke, L Christl, ... JAMA 320 (9), 929-931, 2018 | 28 | 2018 |
| Comparison of propensity score methods for pre-specified subgroup analysis with survival data R Izem, J Liao, M Hu, Y Wei, S Akhtar, M Wernecke, TE MaCurdy, ... Journal of biopharmaceutical statistics 30 (4), 734-751, 2020 | 27 | 2020 |
| Risk factors for COVID-19 deaths among elderly nursing home medicare beneficiaries in the prevaccine period Y Lu, Y Jiao, DJ Graham, Y Wu, J Wang, M Menis, Y Chillarige, ... The Journal of infectious diseases 225 (4), 567-577, 2022 | 25 | 2022 |
| Mortality among Parkinson’s disease patients treated with pimavanserin or atypical antipsychotics: an observational study in medicare beneficiaries AD Mosholder, Y Ma, S Akhtar, GD Podskalny, Y Feng, H Lyu, J Liao, ... American Journal of Psychiatry 179 (8), 553-561, 2022 | 24 | 2022 |
